II
VIVO

Ibex Investors’s Meridian Bioscience Inc VIVO Stock Holding History

Ibex Investors’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-12,790
Closed -$222K – 145
2018
Q4 		$222K Buy
+12,790
New +$218K 0.04% 99
2018
Q2 		– Sell
-20,715
Closed -$294K – 254
2018
Q1 		$294K Buy
+20,715
New +$307K 0.24% 135

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
SFM
Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return

Ibex Investors's VIVO Position: Q1 2019 in Review

Ibex Investors sold out of Meridian Bioscience Inc (VIVO) in Q1 2019, closing a stake of 12,790 shares — an estimated $222K sold.

Ibex Investors first reported a position in VIVO in Q1 2018 and held it in 2 quarters. The position peaked at $294K in Q1 2018. 183 funds tracked by Wall St. Rank hold VIVO as of Q1 2019.

  • Ibex Investors reported no remaining Meridian Bioscience Inc position as of Q1 2019 after selling out during the quarter.
  • Ibex Investors sold 12,790 Meridian Bioscience Inc shares in Q1 2019, an estimated $222K.
  • Ibex Investors first reported a position in Meridian Bioscience Inc in Q1 2018 and held it in 2 quarters.
  • Ibex Investors's Meridian Bioscience Inc position peaked at $294K in Q1 2018.
  • 183 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2019.

Based on Ibex Investors's 13F filing for Q1 2019, filed 7 May 2019.